Stuart L. Emanuel - Concepedia

Author

Stuart L. Emanuel

Johnson & Johnson (United States)

Also Known As

Emanuel, Stuart L., S Emanuel, S L Emanuel, S.L. Emanuel, Stuart Emanuel, Stuart L. Emanuel, Stuart L. Emanuel

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)Bristol-Myers Squibb (United States)Johnson University Bristol-Myers Squibb (Germany)

About

Stuart L. Emanuel is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	31	1.9K
2	Natural Sciences	17	19	870
3	Biochemistry	16	17	806
4	Cell Biology	5	5	400
5	Biomolecular Engineering	3	3	207

Stuart L. Emanuel

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Identification and sequence of an accessory factor required for activation of the human interferon γ receptor Jaemog Soh, Robert Donnelly, Serguei V. Kotenko, Cell CytokineMolecular ImmunologyImmunogeneticsImmunodeficienciesViral Immunity	1994	263
1-Acyl-1<i>H</i>-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis and Evaluation of Biological Activities Ronghui Lin, Peter J. Connolly, Shenlin Huang, Journal of Medicinal Chemistry Selective Cdk1Medicinal ChemistryRepresentative Compound 3BMedicinePharmacological Agent	2005	126
The <i>In vitro</i> and <i>In vivo</i> Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases Stuart L. Emanuel, Catherine A. Rugg, Robert H. Gruninger, Cancer Research Dual InhibitorCell DeathTotal Cumulative DoseCell CycleCancer Biology	2005	122
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors Ronghui Lin, George Chiu, Yang Yu, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineRational Drug DesignPharmacological AgentPharmacotherapy	2007	121
Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor Shenlin Huang, Ronghui Lin, Yang Yu, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryHeterocyclicBiochemistryMedicineNatural Sciences	2006	108
EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. David R. Hurwitz, Stuart L. Emanuel, Margaret Nathan, Journal of Biological Chemistry Epidermal Growth FactorImmunologyDermatologyCell GrowthViral Structural Protein	1991	101
Discovery of anticancer agents of diverse natural origin A. Douglas Kinghorn, Esperanza J. Carcache de Blanco, Hee‐Byung Chai, Pure and Applied Chemistry	2009	101
Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors Gee‐Hong Kuo, A. DeAngelis, Stuart L. Emanuel, Journal of Medicinal Chemistry Combinatorial ChemistryOrganic ChemistryPharmacotherapyNew SeriesHeterocycle Chemistry	2005	92
4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors Guozhang Xu, M.C. Abad, Peter J. Connolly, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicinePharmacotherapyAnti-cancer Agent4-Amino-6-arylamino-pyrimidine-5-carbaldehyde Hydrazones	2008	88
Structures of Adnectin/Protein Complexes Reveal an Expanded Binding Footprint Vidhyashankar Ramamurthy, Stanley R. Krystek, Alexander A. Bush, Structure	2012	88

Page 1